Abstracts tagged "Vasculitis"

Abstract Number: 2417 • ACR Convergence 2023
Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study
LUIGI BOIARDI¹, PIERLUIGI MACCHIONI², Francesco Muratore³, Elena Galli⁴, chiara marvisi⁴, caterina Ricordi⁴, federica Macaluso¹, alberto cavazza⁴, Stefania Croci⁴ and Carlo Salvarani⁵, ¹IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁵Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our…
Abstract Number: 2599 • ACR Convergence 2023
Study of the Role of interleukin-17 in Giant Cell Arteritis
helene Greigert¹, andre ramon², corentin Richard³, claudie cladière⁴, Marion CIUDAD⁵, catherine creuzot-garcher⁶, laurent martin⁷, Sylvain AUDIA¹, romain boidot³, Bernard Bonnotte¹ and Maxime Samson¹, ¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Rheumatology, Dijon University Hospital, Dijon, France, ³Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Dijon, France, ⁶Department of Ophthalmology, Dijon University Hospital, Dijon, France, ⁷Department of Pathology, Dijon University Hospital, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis in which Th17 cells have been identified in excess in lesions and in the blood of patients.…
Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Erika Biegelmeyer¹, Mariana Freitas de Aguiar¹, Priscila Dias Cardoso Ribeiro¹, Ketty Lysie Libardi Lira Machado², Maria da Penha Gomes Gouveia², Camila Maria Paiva França Telles³, Samuel Elias Basualto Dias³, Natália Sarzi Sartori⁴, Thaís Evelyn Karnopp⁵, Vanessa de Oliveira Magalhães¹, Flávia Maria Matos Melo Campos Peixoto¹, Laiza Hombre Dias², Débora Marques Veghini², Rodrigo Vieira de Rezende⁶, Katia Lino Baptista⁶, Ana Karla Guedes de Melo⁷, Vitor Alves Cruz⁸, Maria Cecília Dias Corrêa⁹, Adriana Maria Kakehasi¹⁰, Rejane Maria Rodrigues de Abreu Vieira¹¹, Valderilio Feijó Azevedo¹², Olindo Assis Martins-Filho¹³, Charlles Heldan de Moura Castro¹, Ricardo Xavier¹⁴, Andréa Teixeira-Carvalho¹³, Viviane Angelina de Souza⁹, Odirlei André Monticelo¹⁵, Marcelo Pinheiro¹⁶, Edgard Torres dos Reis Neto¹, Emilia Sato¹, Gilda Ferreira¹⁷, Gecilmara Pileggi¹⁸, Valeria Valim¹⁹ and Alexandre wagner Silva de Souza²⁰, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, ³Universidade Federal do Amazonas, Manaus, Brazil, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal Fluminense, Niterói, Brazil, ⁷Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, ⁸Universidade Federal de Goiás, Goiânia, Brazil, ⁹Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, ¹⁰Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹¹Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, ¹²Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, ¹³Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, ¹⁴Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁵Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁶UNIFESP/ EPM, São Paulo, Brazil, ¹⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁸UNIFESP, Ribeirão Preto, Brazil, ¹⁹Universidade Federal do Espírito Santo, Vitória, Brazil, ²⁰Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…
Abstract Number: 0700 • ACR Convergence 2023
A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta
Elaine Yacyshyn, Simran Gulati, Whitney Hung, Don Voaklander and Allyson Jones, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Systemic vasculitis encompasses a group of autoimmune diseases involving inflammation of blood vessels. Although a rare disease, vasculitis can present with life-threatening symptoms which…
Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Caleb Bolden¹, Claire Cook¹, Lucy Finkelstein-Fox¹, Xiaoqing Fu¹, Flavia Castelino¹, Hyon K. Choi², Cory Perugino¹, John Stone³, Elyse Park¹, Zachary Wallace⁴ and Daniel Hall¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…
Abstract Number: 1543 • ACR Convergence 2023
The Association of Frailty with Outcomes in Patients with Vasculitis
Sebastian Sattui¹, John Stadler², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Peter Merkel⁴ and Robert Spiera⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Hosptial for Special Surgery, New York, NY
Background/Purpose: Frailty is associated with poor health outcomes including increased risk of hospitalizations, infections, and fractures. In the baseline survey of the VascStrong study, we…
Abstract Number: 1646 • ACR Convergence 2023
The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis
Keren Port¹, Ivan Ho Shon¹, Sally Ayesa¹, Rachel Langford¹, Olivia Bennett¹, Andrew Csillag¹, Stacey Fredericks¹, Luz Palacios-Derflingher², Eva Wegner¹ and Anthony Sammel¹, ¹The Prince of Wales Hospital, Sydney, Australia, ²University of New South Wales, Sydney, Australia
Background/Purpose: GCA is a systemic medium-large vessel vasculitis (M-LVV) involving the cranial arteries, aorta and its major branches. Recent studies have shown that PET/CT including…
Abstract Number: 2394 • ACR Convergence 2023
18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Paula V. Estrada-Alarcón¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maria. T Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galindez-Agirregoikoa¹⁰, javier Mendizábal¹¹, lydia Abasolo¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Patricia Moya¹⁵, patricia Moran Alvarez¹⁶, Vanesa Navarro¹⁷, Carles Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Alicia García²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸, Ricardo Blanco²⁹ and On Behalf of ARTESER Working Group³⁰, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Basurto University Hospital, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²Hospital Clínico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, Islas Canarias, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰SER, Spain
Background/Purpose: Imaging studies in patients with giant cell arteritis (GCA) and suspected large vessel vasculitis (LVV) are sensitive, increasingly available, and less aggressive than temporal…
Abstract Number: 2418 • ACR Convergence 2023
Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴, Grainne Murphy⁵ and David Kane⁶, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Cork University Hospital, Cork, Ireland, ⁶Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 0236 • ACR Convergence 2023
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
orrin Troum¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹University of Southern California Keck School of Medicine and Providence Saint John's Health Center, Santa Monica, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is associated with high comorbidity, including cardiovascular (CV), metabolic, and renal disease,1 with even higher burden in uncontrolled gout patients (pts).2 CV (myocardial…
Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Jose Luis Martin-Varillas³, Carmen Alvarez Reguera¹, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Raul Fernandez¹, Ivan Ferraz Amaro⁶, Jose Luis Hernandez¹ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital de Sierrallana, Santander, Spain, ⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
Abstract Number: 0853 • ACR Convergence 2023
Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
Shruthi Srivatsan¹, Zachary Williams¹, Claire Cook¹, Xiaoqing Fu¹, Naomi Patel¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-to-medium vessel vasculitis associated with substantial morbidity and mortality, in part due to glucocorticoid exposure. Avacopan, an oral C5a…
Abstract Number: 1546 • ACR Convergence 2023
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Ricardo Blanco¹, Iñigo Rúa-Figueroa², Roser Solans³, Maria C Cid⁴, Marina Blanco⁵, Ismael Garcia Moguel⁶, Francisco Perez Grimaldi⁷, Ana Noblejas⁸, Moises Labrador³, Cristian Domingo⁹, Georgina espigol¹⁰, Fernando Sanchez Toril¹¹, Francisco Ortiz-Sanjuán¹², Ebymar Arismendi¹³ and Jose María Alvaro-Gracias¹⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ³Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, ⁶Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, ⁷Pneumology Department, H. University of Jerez, Cádiz, Spain, ⁸Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, ⁹Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁰Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, ¹¹Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, ¹²Hospital Universitario y Politécnico La Fe, Valencia, Spain, ¹³Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…
Abstract Number: 1650 • ACR Convergence 2023
Optic Nerve Sheath Measurement as a Disease Activity Biomarker in Giant Cell Arteritis
Carolyn Ross¹, Stephanie Ducharme-Benard², Samer Hussein³, Rosalie-Selene Meunier³, Christian Pagnoux⁴ and Jean-Paul Makhzoum¹, ¹Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Recently, optic nerve sheath (ONS) enhancement using contrast-enhanced magnetic resonance imaging of the brain and orbits was observed in most patients with biopsy-proven GCA.…

« Previous Page
1
…
8
9
10
11
12
…
35
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].